GlassScriptPhysician profile
Jennifer Poucher
NPI 1255084976
$2,157.55
in general payments reported to CMS, 2019-2025
20 companies · $662 in 2025
The $662 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $468 · 2023: $388 · 2024: $640 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.12 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $392.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $163.47 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $150.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Medtronic, INC. | $138.78 | 2022 | |
| Phathom Pharmaceuticals, INC. | $102.12 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $90.43 | 2024-2025 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $85.98 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $59.99 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.34 | 2025 | Jardiance |
| Dexcom, INC. | $43.96 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $43.79 | 2024-2025 | Holter, (Ak6) Vest Therapy |
| Pfizer INC. | $40.30 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.36 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $18.25 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.19 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $16.62 | 2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $15.66 | 2025 | Fanapt |
| Radius Health, INC. | $14.64 | 2023 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Poucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.